IL238588B - Anti-flt-1 antibodies in the treatment of Duchenne muscular dystrophy - Google Patents
Anti-flt-1 antibodies in the treatment of Duchenne muscular dystrophyInfo
- Publication number
- IL238588B IL238588B IL238588A IL23858815A IL238588B IL 238588 B IL238588 B IL 238588B IL 238588 A IL238588 A IL 238588A IL 23858815 A IL23858815 A IL 23858815A IL 238588 B IL238588 B IL 238588B
- Authority
- IL
- Israel
- Prior art keywords
- flt
- antibodies
- muscular dystrophy
- duchenne muscular
- treating duchenne
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361757571P | 2013-01-28 | 2013-01-28 | |
| PCT/US2014/013402 WO2014117160A1 (en) | 2013-01-28 | 2014-01-28 | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL238588A0 IL238588A0 (en) | 2015-06-30 |
| IL238588B true IL238588B (en) | 2020-04-30 |
Family
ID=50073518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238588A IL238588B (en) | 2013-01-28 | 2015-05-03 | Anti-flt-1 antibodies in the treatment of Duchenne muscular dystrophy |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9957324B2 (enExample) |
| EP (1) | EP2948476B1 (enExample) |
| JP (2) | JP6469022B2 (enExample) |
| KR (1) | KR102259255B1 (enExample) |
| CN (1) | CN104955843B (enExample) |
| AU (1) | AU2014209012B2 (enExample) |
| BR (1) | BR112015017242B1 (enExample) |
| CA (1) | CA2898998C (enExample) |
| EA (1) | EA037501B1 (enExample) |
| ES (1) | ES2676406T3 (enExample) |
| HK (1) | HK1213918A1 (enExample) |
| IL (1) | IL238588B (enExample) |
| MX (1) | MX360153B (enExample) |
| WO (1) | WO2014117160A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948164B1 (en) | 2013-01-28 | 2019-04-10 | Shire Human Genetic Therapies, Inc. | Placenta growth factor in treating duchenne muscular dystrophy |
| MA41899A (fr) * | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| US10738123B2 (en) | 2015-04-07 | 2020-08-11 | Shire Human Genetic Therapies, Inc. | Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia |
| CA2981961A1 (en) * | 2015-04-07 | 2016-10-13 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
| KR102019048B1 (ko) | 2017-02-06 | 2019-09-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법 |
| KR101886788B1 (ko) | 2017-02-07 | 2018-08-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| WO2023182657A1 (ko) | 2022-03-24 | 2023-09-28 | 주식회사 케이에스비튜젠 | 항-fetuin-b 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2377555A3 (en) * | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
-
2014
- 2014-01-28 CN CN201480003714.6A patent/CN104955843B/zh active Active
- 2014-01-28 US US14/763,881 patent/US9957324B2/en active Active
- 2014-01-28 CA CA2898998A patent/CA2898998C/en active Active
- 2014-01-28 HK HK16101850.9A patent/HK1213918A1/zh unknown
- 2014-01-28 MX MX2015009690A patent/MX360153B/es active IP Right Grant
- 2014-01-28 JP JP2015555412A patent/JP6469022B2/ja active Active
- 2014-01-28 ES ES14704040.6T patent/ES2676406T3/es active Active
- 2014-01-28 AU AU2014209012A patent/AU2014209012B2/en active Active
- 2014-01-28 KR KR1020157021136A patent/KR102259255B1/ko active Active
- 2014-01-28 EP EP14704040.6A patent/EP2948476B1/en active Active
- 2014-01-28 BR BR112015017242-3A patent/BR112015017242B1/pt active IP Right Grant
- 2014-01-28 WO PCT/US2014/013402 patent/WO2014117160A1/en not_active Ceased
- 2014-01-28 EA EA201590720A patent/EA037501B1/ru unknown
-
2015
- 2015-05-03 IL IL238588A patent/IL238588B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,937 patent/US20180312593A1/en not_active Abandoned
- 2018-11-01 JP JP2018206297A patent/JP2019023230A/ja active Pending
-
2020
- 2020-07-14 US US16/928,819 patent/US20210163603A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2898998C (en) | 2023-02-14 |
| EP2948476B1 (en) | 2018-06-06 |
| AU2014209012B2 (en) | 2018-11-08 |
| EA037501B1 (ru) | 2021-04-05 |
| EA201590720A1 (ru) | 2015-11-30 |
| EP2948476A1 (en) | 2015-12-02 |
| WO2014117160A1 (en) | 2014-07-31 |
| ES2676406T3 (es) | 2018-07-19 |
| HK1217710A1 (en) | 2017-01-20 |
| JP6469022B2 (ja) | 2019-02-13 |
| IL238588A0 (en) | 2015-06-30 |
| US20150361174A1 (en) | 2015-12-17 |
| BR112015017242B1 (pt) | 2023-11-07 |
| BR112015017242A2 (enExample) | 2017-08-15 |
| CN104955843B (zh) | 2019-08-13 |
| JP2019023230A (ja) | 2019-02-14 |
| US20180312593A1 (en) | 2018-11-01 |
| EA201590720A8 (ru) | 2018-09-28 |
| AU2014209012A1 (en) | 2015-05-21 |
| JP2016511234A (ja) | 2016-04-14 |
| CN104955843A (zh) | 2015-09-30 |
| KR20150109386A (ko) | 2015-10-01 |
| US9957324B2 (en) | 2018-05-01 |
| US20210163603A1 (en) | 2021-06-03 |
| KR102259255B1 (ko) | 2021-05-31 |
| MX2015009690A (es) | 2016-03-31 |
| CA2898998A1 (en) | 2014-07-31 |
| MX360153B (es) | 2018-10-24 |
| HK1213918A1 (zh) | 2016-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278912A (en) | Improved preparations for the treatment of muscular dystrophy | |
| IL238588A0 (en) | Anti-flt-1 antibodies in the treatment of Duchenne muscular dystrophy | |
| IL240024B (en) | Polystatin in the treatment of Duchenne muscular dystrophy | |
| HUE042218T2 (hu) | Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére | |
| GB2507596B (en) | Secure computing device and method | |
| PL3660154T3 (pl) | Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a | |
| SG11201507563SA (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
| ZA201408955B (en) | Anti-blys antibody | |
| GB2502503B (en) | Luggage apparatus | |
| GB201219487D0 (en) | Anti-S100A4 antibody molecules and their uses | |
| EP2945593A4 (en) | METHOD OF LYOPHILIZATION | |
| PL2965322T3 (pl) | Miejscowa koncentracja energii | |
| GB201601669D0 (en) | Biosensor | |
| IL236714A0 (en) | Anti-her2 antibodies with reduced fucosylation for use in cancer therapy | |
| GB201420587D0 (en) | Polymer process | |
| GB2509517B (en) | Computing apparatus | |
| PL3280734T3 (pl) | Przeciwciała anty-flt-1 do leczenia dystrofii mięśniowej duchenne'a | |
| SG11201504354SA (en) | Computing device | |
| GB201311269D0 (en) | Processing Transactions | |
| IL245222A0 (en) | A method for discovering DNA | |
| GB2508477B (en) | Computing apparatus and method | |
| PL2986429T3 (pl) | Urządzenie do powlekania profili i sposób powlekania profili | |
| EP2972714A4 (en) | PROVIDING A HYBRID TOUCH PAD ON A COMPUTER DEVICE | |
| GB2519413B (en) | Catalyst and process | |
| EP3010587A4 (en) | Methods of treating muscular dystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |